ReviewReviews in endocrine & metabolic disorders2013
Seaweeds as potential therapeutic interventions for the metabolic syndrome.
Review in Reviews in endocrine & metabolic disorders, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 50 citations in OpenAlex.
- Dietary inflammatory potential in depressive symptoms in older Chinese people in Hong Kong: a cohort study.Frontiers in nutrition · 2026Article
- From Brewery Waste to Sustainable Aquafeed: HarnessingAquaculture nutrition · 2026Article
- Prediction of metabolic syndrome using machine learning approaches based on genetic and nutritional factors: a 14-year prospective-based cohort study.BMC medical genomics · 2024Article
- Impact of Harvest Month and Drying Process on the Nutritional and Bioactive Properties of WildMarine drugs · 2023Article
- Association of Seaweed Consumption with Metabolic Syndrome and Its Components: Findings from the Korean Genome and Epidemiology Study.Foods (Basel, Switzerland) · 2022Article
- Brown SeaweedNutrients · 2021Article
- Dietary iodine, seaweed consumption, and incidence risk of metabolic syndrome among postmenopausal women: a prospective analysis of the Korean Multi-Rural Communities Cohort Study (MRCohort).European journal of nutrition · 2021Article
- Clinical Efficacy of Brown SeaweedsMolecules (Basel, Switzerland) · 2021Review
- Hypotriglyceridemic effects of brown seaweed consumption via regulation of bile acid excretion and hepatic lipogenesis in high fat diet-induced obese mice.Nutrition research and practice · 2020Article
- Supplementation with Sea VegetablesCurrent developments in nutrition · 2020Article
- Therapeutic Effect of Seaweed Derived Xanthophyl Carotenoid on Obesity Management; Overview of the Last Decade.International journal of molecular sciences · 2020Review
- Perspective: The Dietary Inflammatory Index (DII)-Lessons Learned, Improvements Made, and Future Directions.Advances in nutrition (Bethesda, Md.) · 2019Article
- Pharmacokinetic and Tissue Distribution of Fucoidan fromMarine drugs · 2018Article
- Kappaphycus alvarezii as a Food Supplement Prevents Diet-Induced Metabolic Syndrome in Rats.Nutrients · 2017Article
- Dietary supplementation of heat-treatedBiology open · 2017Article
- Seaweed supplements normalise metabolic, cardiovascular and liver responses in high-carbohydrate, high-fat fed rats.Marine drugs · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Seaweeds are a characteristic part of the traditional diet in countries such as Japan and Korea; these countries also have a lower prevalence of metabolic syndrome than countries such as the USA and Australia. This suggests that seaweeds may contain compounds that reduce the characteristic signs of obesity, diabetes, hypertension, fatty liver and inflammation in the metabolic syndrome. Potentially bioactive compounds from seaweeds include polysaccharides, peptides, pigments, minerals and omega-3 fatty acids. This review emphasises current research on these compounds in isolated cells, animal models and patients. Key problems for future research include chemical characterisation of the bioactive principles, defining pharmacological responses in all aspects of the metabolic syndrome, determining if a therapeutic dose has been administered, and defining oral bioavailability of the active ingredients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.